Pain evaluation in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the PARABO observation study

被引：0
|
作者：
Palmedo, H. [1 ]
Eschmann, S. [2 ]
Werner, A. [3 ]
Selinski, I. [4 ]
Moellers, M-O. [5 ]
Kalinovsky, J. [6 ]
Benson, A. [7 ]
Poeppel, T. [8 ]
机构：
[1] Johanniter Hosp, Canc Ctr, Dept Nucl Med, Bonn, Germany
[2] Marien Hosp, Nucl Med, Stuttgart, Germany
[3] Radiol Schwetzingen, Radiol, Schwetzingen, Germany
[4] Goethe Univ Hosp Frankfurt, Ctr Radol, Frankfurt, Germany
[5] Klinikum Westfalen, Nucl Med, Dortmund, Germany
[6] Bayer Consumer Care Switzerland, Global Med Affairs, Basel, Switzerland
[7] Bayer HealthCare Pharmaceut, Stat, Whippany, NJ USA
[8] Univ Hosp Essen, Nucl Med, Essen, Germany
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
860P
引用
收藏
页码：336 / 336
页数：1
相关论文
共 50 条
  • [1] Pain efficacy with radium-223 (Ra-223) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the PARABO observational study
    Palmedo, H.
    Ahmadzadehfar, H.
    Eschmann, S.
    Selkinski, I.
    Straube, F.
    Niesen, A.
    Schoenberger, J.
    Barsegian, V.
    Liepe, K.
    Mottaghy, F. M.
    Guan, R.
    Pinkert, J.
    Buetikofer, S.
    Herrmann, K.
    ANNALS OF ONCOLOGY, 2021, 32 : S641 - S641
  • [2] Safety outcomes and pain responses in the REASSURE observational study of radium-223 (Ra-223) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Conti, Peter
    George, Saby
    Tomaszewski, Jeffrey
    Song, Daniel
    Harshman, Lauren
    Nordquist, Luke
    Sandstrom, Per
    Bayh, Inga
    Babajanyan, Svetlana
    Sartor, Oliver
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [3] Pain response and clinical outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223): Final results from a prospective, noninterventional study (PARABO)
    Palmedo, H.
    Ahmadzadehfar, H.
    Eschmann, S.
    Selkinski, I.
    Niesen, A.
    Schonberger, J.
    Barsegian, V.
    Liepe, K.
    Mottaghy, F. M.
    Guan, R.
    Pinkert, J.
    Buetikofer, S.
    Herrmann, K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S313 - S314
  • [4] Symptomatic skeletal event (SSE) dynamics in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223): An interim review of a prospective, noninterventional study (PARABO)
    Poeppel, T.
    Eschmann, S.
    Werner, A.
    Selkinski, I.
    Moellers, M-O.
    Neusser, T.
    Benson, A.
    Kalinovsky, J.
    Palmedo, H.
    ANNALS OF ONCOLOGY, 2018, 29 : 289 - +
  • [5] Fracture risk after radium-223 (Ra-223) in metastatic castration resistant prostate cancer (mCRPC).
    Alonzi, Roberto
    Parker, Chris C.
    Tunariu, Nina
    Koh, Dow-Mu
    Staffurth, John
    Blackledge, Matthew D.
    Padhani, Anwar R.
    Tree, Alison
    Stidwill, Helen
    Finch, Jessica
    Chatfield, Peter
    Perry, Sophie
    Tovey, Holly
    Hall, Emma
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] Fracture risk in men with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra 223)
    Hijab, A.
    Tunariu, N.
    Tovey, H.
    Alonzi, R.
    Tree, A.
    Staffurth, J.
    Blackledge, M.
    Padhani, A. R.
    Stidwill, H.
    Finch, J.
    Chatfield, P.
    Perry, S.
    Koh, D-M.
    Hall, E.
    Parker, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S539 - S539
  • [7] Radium-223 (Ra-223) in asymptomatic metastatic castration-resistant prostate cancer (mCRPC) patients treated in an international early access program (iEAP).
    Heidenreich, Axel
    Gillessen, Silke
    Heinrich, Daniel
    Keizman, Daniel
    O'Sullivan, Joe M.
    Carles, Joan
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [8] Pain efficacy with radium-223 (Ra-223) in the REASSURE global, prospective, observational study of men with metastatic castration-resistant prostate cancer (mCRPC)
    Higano, C. S.
    Dizdarevic, S.
    Sundar, S.
    Agarwal, N.
    Essler, M.
    Song, D.
    George, S.
    Shore, N. D.
    Kurtinecz, M.
    Verholen, F.
    Sandstrom, P.
    Sartor, O.
    George, D. J.
    ANNALS OF ONCOLOGY, 2021, 32 : S640 - S641
  • [9] Alkaline phosphatase (ALP) decline and overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the REASSURE study.
    James, Nicholas D.
    Heinrich, Daniel
    Castro, Elena
    George, Saby
    Song, Daniel Y.
    Dizdarevic, Sabina
    Baldari, Sergio
    Essler, Markus
    De Jong, Igle Jan
    Lastoria, Secondo
    Hammerer, Peter G.
    Meltzer, Jeffrey
    Sandstrom, Per
    Verholen, Frank
    Tombal, Bertrand F.
    O'Sullivan, Joe M.
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] Safety and overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) plus subsequent taxane therapy.
    Higano, Celestia S.
    Harshman, Lauren C.
    Dizdarevic, Sabina
    Logue, John
    Richardson, Timothy
    George, Saby
    Song, Danny
    de Jong, Igle J.
    Tomaszewski, Jeffrey
    Saad, Fred
    Miller, Kurt
    Meltzer, Jeffrey
    Sandstrom, Per
    Tombal, Bertrand F.
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345